Medical Device and Wound Care News and Analysis Blog

Orthobiologic Care: Inside the Agenda at TOBI Conference 2025

Written by David Shepard | 9/30/25 1:30 PM

Dr. Steve Sampson, founder of The Orthopedic Institute (TOBI) and the Orthohealing Center, discusses the evolution of orthobiologics, highlighting the integration of machine-based therapies like shockwave and a focus on patient safety, with patients traveling overseas for untested biologic treatments. 

In this interview with SmartTRAK, TOBI founder Steve Sampson, DO, discusses the development of orthobiologics, highlighting a key inflection point where technologies like shockwave and light therapy are used to boost the body's natural healing process. Dr. Sampson also mentions patients traveling abroad for treatments. He warns about the lack of regulatory oversight, potential complications and offers solutions through the Orthohealing Alliance.

Click on the following video (11:10 min) to learn more. A link to download a complete transcript of the interview is provided below.


SmartTRAK: My name is David Shepard. I'm with SmartTRAK, and I'm here at the 16th annual TOBI meeting. and it's my pleasure to be joined by Dr. Steve Sampson. Thanks so much for taking the time. I really appreciate it.

Steve Sampson, DO: Thanks for having me. Looking forward to chatting.

Absolutely. So, the agenda of this year's conference is... It's got a wide range of topics. What do you think is reflected in this year's agenda that really typifies the technologies that are happening out there in the field today?

SS: It's probably the most exciting time in my 20-year career that I feel like we're at this inflection point with new technologies, including machine-based therapies. So, the concept is the human body is remarkable, and we're made of 37 trillion cells, and we have our own drug store, our own ability to self-repair. Our role as physicians is to try to facilitate that. So, machine-based treatments are a big point of this conference where there's a session on shockwave therapy, photo-biomodulation light therapy, hyperbaric oxygen. They're all different machine-based treatments that are trying to boost our body's healing capacity. Then I also have a new session of mesenchymal stem cells or MSCs overseas.

SS: A lot of times, in clinic, we find patients are going to Mexico, Panama, Thailand, and some of them have unlimited resources, but they may not be getting the best level of care and bigger isn't always better.

Right.

SS: So, understanding what are some of the regulatory challenges here in the United States, why are patients going overseas ,,,

Click the button to get the full transcript of our exclusive interview with TOBI founder Steve Sampson, DO, conducted by David Shepard, SmartTRAK GM/Sr Analyst, Orthobio & Regen.

SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s proprietary methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services. If you would like a demo of what SmartTRAK has to offer and see how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.